Dr. Kimberley Doucette, MD

Dr. Doucette practices at Medstar Georgetown Medical Center in Washington, District of Columbia.

Dr. Doucette's NPI, 1750776837, was assigned on April 5, 2015. Dr. Doucette holds District of Columbia license MD046221.

Dr. Doucette's primary practice is Medstar Georgetown Medical Center, at 3800 Reservoir NW Rd, Washington, DC 20007 in District Of Columbia County. The practice phone is (202) 444-1400.

Dr. Doucette's primary practice is Medstar Georgetown Medical Center in Washington, District of Columbia. Dr. Doucette is also affiliated with MedStar Washington Hospital Center. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Doucette to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Doucette practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Doucette's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Doucette is licensed in District of Columbia.

CMS data shows 1,385 Medicare services from Dr. Doucette across 7 procedure codes in 2024, for 215 Medicare patients. Medicare paid $109,594 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 215 Medicare patients who saw Dr. Doucette in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Doucette's median patient age at 68, with 50% women.

In 2024, Dr. Doucette wrote 164 Medicare Part D claims for 51 patients. 69% of them were for generic drugs. CMS names the drug for 45 of them, across 3 drugs with 11 or more claims each, at $200,238 in total drug cost. In 2023, CMS named 38 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Doucette for performance year 2024. Dr. Doucette accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Doucette as offering telehealth.

Dmand AI links 16 papers to Dr. Doucette, published from 2012 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute and Transplantation, Homologous. Dr. Doucette has published most often in Bone Marrow Transplant. Dr. Doucette's most frequent co-authors are Judith Karp, MD, Bryan Lee Chan, MD, MPH and Kelly West Fitzpatrick, MD.

CMS Open Payments shows 82 general payments to Dr. Doucette from 22 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 58% of the total. Sanofi and Genzyme US Companies paid the most, $3,142. It also lists 2 research payments totaling $1,880 in 2022.